5 software found
Certara Software
-
Phoenix PK/PD Software
-
Phoenix - Version WinNonlin - Industry Standard for Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis Software
PK/PD and non-compartmental analyses can be time consuming, requiring detailed attention to every step from data preparation to report generation. Phoenix WinNonlin™’s integrated tools for data processing, graphing & charting, report generation, and compliance create an efficient, all-in-one collaboration workbench. Phoenix WinNonlin is used by over 10,000 scientists at more than 1,500 establishments in 60 countries. It is the industry ...
-
Phoenix - Version 8.3 - Pharmacokinetic and Pharmacodynamic (PK/PD) Platform
The one software ecosystem to streamline your PK/PD data management and analysis; With all the tools you need in a single, interoperable platform, effortlessly share pre-clinical and clinical knowledge across your organization through secure and consistent workflows using Phoenix-based tools and 3rd-party applications. Phoenix WinNonlin is the first choice for non-compartmental analysis (NCA), toxicokinetic modeling, and pharmacokinetic and ...
-
Phoenix NLME - Version 8.3 - Modern Population PK/PD Modeling Tool
Phoenix NLME lets you focus on your models, not the tools required to implement the models. Phoenix NLME is a population modeling and simulation software for scientists with varying levels of experience—from novice PK/PD scientists to the most advanced modelers. This comprehensive package includes integrated data preparation, modeling, and graphics tools with the same user interface that is used in Phoenix WinNonlin. 18 of the top 20 ...
-
Simcyp Mechanistic Software
-
Simcyp - Version 21 - PBPK Simulator
The Simcyp Simulator is the pharmaceutical industry’s most sophisticated physiologically based pharmacokinetics (PBPK) platform for determining first-in-human dosing, optimizing clinical study design, evaluating new drug formulations, setting the dose in untested populations, performing virtual bioequivalence analyses, and predicting drug-drug interactions (DDIs). Simcyp is being applied to small molecules, biologics, ADCs, generics, and new ...
-
Simcyp - Biological Medicines Simulator
Biological medicines (“biologics” or “large molecule drugs”) now account for 30% of new drug approvals and up to 50% of the pharmaceutical industry’s pipeline. Biologics differ from small molecules because they are much larger, have slower absorption rates, confined distribution, and different elimination. They are designed for a specific target, typically found on the cell membrane, which they bind to with high affinity. Due ...